Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InsmedMEX:INSM 73 Beneish M-Score is -0.71 as of Aug. 22, 2026. GuruFocus rates MEX:INSM with a GF Score™ of 73/100 and a GF Value™ of MXN3,415.35 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 828 Biotechnology companies, Insmed ranks worse than 79.23% on this metric.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Warning Sign:
Beneish M-Score -0.71 higher than -1.78, which implies that the company might have manipulated its financial results.
The historical rank and industry rank for Insmed's Beneish M-Score or its related term are showing as below:
MEX:INSM'
s Beneish M-Score Range Over the Past 10 Years
Min: -3.38 Med: -2.47 Max: 8.47
Current: -0.71
During the past 13 years, the highest Beneish M-Score of Insmed was 8.47. The lowest was -3.38. And the median was -2.47.
The historical data trend for Insmed's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:INSM vs INCY, BNTX, MRNA: Beneish M-Score Comparison
For the Biotechnology subindustry, Insmed's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insmed Beneish M-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Insmed's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Insmed's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Insmed for today is based on a combination of the following eight different indices:
M
=
-4.84
+
0.92 * DSRI
+
0.528 * GMI
+
0.404 * AQI
+
0.892 * SGI
+
0.115 * DEPI
=
-4.84
+
0.92 * 1.4178
+
0.528 * 0.9077
+
0.404 * 1.4018
+
0.892 * 2.5573
+
0.115 * 0.7616
-
0.172 * SGAI
+
4.679 * TATA
-
0.327 * LVGI
-
0.172 * 0.5571
+
4.679 * -0.059574
-
0.327 * 1.3513
=
-0.94
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI
=
(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))
/
(Depreciation_t / (Depreciaton_t + PPE_t))
=
(245.676 / (245.676 + 2207.291))
/
(355.649 / (355.649 + 2348.688))
=
0.100155
/
0.131511
=
0.7616
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA
=
(IncomefromContinuingOperations_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(NetIncome_t - NonOperatingIncome_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(-15882.884 - 358.745
-
-14056.007)
/
36687.657
=
-0.059574
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Insmed has a M-score of -0.94 signals that the company is likely to be a manipulator.
Insmed (MEX:INSM) has a Beneish M-Score of -0.71 as of Aug. 22, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Insmed and its competitors. According to the industry distribution chart, Insmed ranks #656 out of 828 companies in the Biotechnology industry, placing it in the top 79.2%.
Is Insmed's Beneish M-Score too high?
Insmed's current Beneish M-Score is -0.71. Based on the distribution chart, Insmed ranks #656 out of 828 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Insmed has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Insmed's Beneish M-Score compare to INCY and BNTX?
According to the Biotechnology industry distribution chart, Insmed ranks #656 out of 828 companies for Beneish M-Score. This places Insmed in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Insmed and its competitors. Insmed's current Beneish M-Score is -0.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insmed stock overvalued right now?
Based on GuruFocus' analysis, Insmed (MEX:INSM) is currently considered Possible Value Trap. The stock's GF Value™ is MXN3,415.35, compared to a current price of MXN2,135.00 — trading 37.5% below its estimated fair value. The current Beneish M-Score is -0.71. Insmed's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Insmed (MEX:INSM), the current Beneish M-Score is -0.71 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insmed (MEX:INSM) Overvalued in 2026?
Based on GuruFocus' analysis, Insmed stock appears to be undervalued.
The current stock price of MXN2,135.00 is trading 37.5% below its estimated GF Value™ of MXN3,415.35.
GuruFocus considers Insmed to be Possible Value Trap.
Key valuation signals for MEX:INSM:
Beneish M-Score: -0.71
GF Value™: MXN3,415.35 vs. price of MXN2,135.00 (37.5% below fair value)
No single metric tells the full story. See the MEX:INSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
73GF Score
Get the complete analysis for MEX:INSM
Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:INSM has been successfully added to your 
